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Abstract
In our previous work we could identify defects in human regulatory T cells (Tregs) likely fa-
voring the development of graft-versus-host disease (GvHD) following allogeneic stem cell
transplantation (SCT). Treg transcriptome analyses comparing GvHD and immune tolerant
patients uncovered regulated gene transcripts highly relevant for Treg cell function. More-
over, granzyme A (GZMA) also showed a significant lower expression at the protein level in
Tregs of GvHD patients. GZMA induces cytolysis in a perforin-dependent, FAS-FASL inde-
pendent manner and represents a cell-contact dependent mechanism for Tregs to control
immune responses. We therefore analyzed the functional role of GZMA in a murine stan-
dard model for GvHD. For this purpose, adoptively transferred CD4+CD25+ Tregs from
gzmA-/- mice were analyzed in comparison to their wild type counterparts for their capability
to prevent murine GvHD.GzmA-/- Tregs home efficiently to secondary lymphoid organs and
do not show phenotypic alterations with respect to activation and migration properties to in-
flammatory sites. Whereas gzmA-/- Tregs are highly suppressive in vitro, Tregs require
GZMA to rescue hosts from murine GvHD, especially regarding gastrointestinal target
organ damage. We herewith identify GZMA as critical effector molecule of human Treg
function for gastrointestinal immune response in an experimental GvHD model.
Introduction
Regulatory T cells (Tregs) play a critical role in the induction and maintenance of peripheral
tolerance in allogeneic stem cell transplantation (SCT). Experiments in graft-versus-host dis-
ease (GvHD) model systems have shown that removal of CD4+CD25+ Tregs from the donor al-
lograft accelerates GvHD, whereas the adoptive transfer of Tregs inhibits the allogeneic
immune response [1–4]. Recently, SCT qualified as first venue for donor Treg cell infusion and
revealed promising results [5]. Especially in HLA-haploidentical SCT coinfusion of regulatory
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and conventional T cells protects against GvHD and prevents acute leukemia relapse in high
risk patients [6]. In the last decade, surface molecules, transcription factors, and soluble mole-
cules have been identified that are highly important for the induction of in vivo tolerance by
Tregs [7]. As functional data for regulatory T cells are very rare, our recent data studying the
human Treg transcriptome following allogeneic SCT are highly relevant [8]. This comparative
analysis in more than 140 patients with and without GvHD gives a global view on immune ho-
meostasis of Tregs in the allogeneic setting. We identified several key molecules likely responsi-
ble for defective Treg function in GvHD patients with regards to their suppressive capacity
(i.e., GZMA) and migration to inflammatory sites (i.e., CXCR3, CCR5). Tregs of GvHD pa-
tients show a significant lower expression of GZMA early after SCT in comparison to immune
tolerant patients never developing a GvHD, but stable expression levels of granzyme B
(GZMB). Thereby, our results are well in line with murine data demonstrating that GZMB is
not required for Treg cell mediated suppression of GvHD [9]. Notably, to our knowledge the
functional role of GZMA has not been tested for Treg cell mediated GvHD prevention. The
proposed functions of granzymes are multifaceted including induction of cell death and in-
flammation [10]. Several groups demonstrated that human Tregs can use the granzyme/
perforin pathway to suppress effector T cell proliferation and effectively kill autologous im-
mune cells including activated CD4+ and CD8+ T cells and dendritic cells [11–13]. GZMA is
the most abundant serine protease that has been proposed to induce a caspase-independent
cell death in the target cells [14]. With respect to our data from human Treg transcriptome
study [8], we here examined the role of GZMA in a haploidentical murine GvHD model using
gzmA-/- donor Tregs to clarify the functional relevance of GZMA for Treg-mediated suppres-
sion of GvHD.
Material and Methods
Information on animal experiments
The animal experiments were performed in accordance to the guidelines and approval by Nie-
dersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit (Application
number: 33.9-42502-04-09/1644). All efforts were made to prevent animal suffering. In addi-
tion, mice numbers were kept as small as necessary for appropriate statistical analyses. During
the experiments mice were monitored twice daily for any signs of pain and distress according
to the Cooke Score, which includes parameters as activity, weight loss and posture (see also de-
scription of the GvHDmodel later in this section). The optimal irradiation dose has been titrat-
ed to the lowest possible dose of 8 Gy during the establishment of the GvHDmodel at the
Hannover Medical School according to the animal research application (see above). To mini-
mize suffering of animals mice were sacrified latest after 4 weeks by cervical dislocation. Nota-
bly, experiments were discontinued at an earlier timepoint for animals with a body weight loss
of more than 20% and a Cooke score of more than 10. gzmA-/- mice were kindly provided by
Julian Pardo, Immune Effector Cells Group (ICE), Aragón Health Research Institute (IIS Ara-
gón), Edificio CIBA, Biomedical Research Centre of Aragon (CIBA), Zaragoza. Cell popula-
tions used in the experiments within this manuscript have been freshly isolated from mice. No
cell lines or human tissue have been used.
Treg isolation and phenotypic characterization
CD4+ T cells from wildtype (WT) and gzmA-/- mice (the genotype was analyzed as described
elsewhere [15,16]) were enriched from splenocytes using CD4+ T cell isolation kit (Miltenyi
Biotech, Germany). Negative selection of CD4+CD25+ Tregs and positive enrichment of
CD4+CD25- T effector cells from splenocytes was performed using mouse CD4+25+ regulatory
Granzyme A in Gastrointestinal GvHD
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T cell isolation kit (Miltenyi Biotech, Germany). Total CD4+25+ Treg cells isolated from pe-
ripheral lymph nodes and spleens of WT and gzmA-/- mice were stained with anti-mouse CD4
FITC, anti-mouse CD25 PE, anti-mouse CD44 APC-Cy7, anti-mouse ICOS A647, anti-mouse
CD62L PerCp and anti-mouse CXCR3 Pe-Cy7, measured by FACS Canto and analyzed and
calculated using FloJo Software (gating strategies are presented in S1 and S2 Figs).
Inhibition of proliferation
The suppressive capacity of WT and gzmA-/- Tregs was determined as described earlier [17].
Briefly, 5x104 autologous CD4+CD25- T responder (Tresp) cells were stained with 0.5 μM
CFSE (Invitrogen) according to the manufacturer’s protocol. CFSE-stained Tresp were activat-
ed with αCD3/αCD28 mouse Dynabeads (Gibco) and cultured in the presence of WT or
gzmA-/- Tregs isolated from spleen in RPMI 1640 containing Glutamax medium (Gibco) sup-
plemented with 10% FCS (Biochrom), 50 μg/ml gentamycin (Sigma Aldrich) and 50 μg/ml
penicillin/streptomycin (Sigma Aldrich) at ratios of 1:2, 1:1, 2:1 and 4:1. After seven days cells
were analyzed by FACS Canto (BD). Percentage of suppression was calculated as followed:
100—(percentage of proliferated Tresp x 100 / percentage of proliferated Tresp).
Adoptive transfer of Tregs in a GvHDmouse model
The standard model for acute GvHD (C57BL/6 (H-2Kb)! BALB/c (H-2Kd)) [3] with a total
body irradiation of 800cGy followed by i.v. tail injection of T cell depleted bone marrow (TCD
BM) cells followed by adoptive transfer of effector T cells with and without Tregs for determi-
nation of in vivo effects. In more detail, as stem cell source for transplantation enriched bone
marrow cells were isolated fromWTmice using the CD90.2 microbeads (Miltenyi Biotech,
Germany). CD4+ T cells were enriched from splenocytes using CD4+ T cell isolation kit (Milte-
nyi Biotech, Germany). Negative selection of WT and gzmA-/- CD4+CD25+ Tregs and positive
enrichment of WT CD4+CD25- T effector cells from splenocytes was performed using mouse
CD4+25+ regulatory T cell isolation kit (Miltenyi Biotech, Germany). Purity of all T cell popu-
lations were assessed by flow cytometry using antibodies against CD4, CD25, CD19 (marker
for B cells), CD8 (marker for cytotoxic T cells), CD11c (marker for dendritic cells) and erythro-
cyte marker Gr1. Following isolation and FACS analyses TCD BM and isolated T cell popula-
tions of C57/BL6 (WT) and gzmA-/- donor mice (purity> 95%), respectively were transferred
into BALB/c recipient mice after lethal irradiation. Mice receiving TCD BM (5x106), WT
CD4+CD25- Teff and WT Tregs (each 0.25x106) represented the immune tolerant control
group (group A, n = 3), whereas recipients with adoptively transferred TCD BM (5x106) and
WT CD4+CD25- Teff (0.25x106) without Treg transfer represented the GvHD group (group B,
n = 3). Group C (n = 3) comprised mice receiving TCD BM (5x106) + WT CD4+CD25- Teff
and gzmA-/- Tregs (each 0.25x106). After adoptive T cell transfer the incidence, severity and
clinical manifestation of GvHD was monitored comparatively in the 3 groups by clinical and
histopathological grading. The clinical GvHD scoring was performed for weight loss, posture,
activity, fur texture and skin integrity from 0–10 according to Cooke and colleagues [18]. For
histopathological investigations and scoring, the spleen as well as the GvHD target organs liver,
small and large intestine of sacrificed mice were collected after 3 weeks and analyzed in a
blinded manner at the Faculty of Veterinary Medicine, Department of Veterinary Pathology
(Freie Universität Berlin, Berlin, Germany).
Granzyme A in Gastrointestinal GvHD
PLOSONE | DOI:10.1371/journal.pone.0124927 April 30, 2015 3 / 9
Results
Phenotypic characterization of gzmA-/- Tregs efficiently homing to
secondary lymphoid organs
Wild type (WT) mice and gzmA-/- mice were compared for Treg cell number and expression of
surface marker differentiating naïve, activated and memory T cells (CD62L, CD44). Further-
more, the expression of CXCR3 was analyzed on the respective CD4+CD25+ Treg cell popula-
tion in order to characterize the properties of Tregs to migrate to Th1-associated inflammatory
sites. For this purpose immune cells were prepared from spleens and peripheral lymph nodes
and comparatively analyzed by FACS. Absolute Treg numbers in spleen and peripheral lymph
nodes fromWT and gzmA-/- mice did not show significant differences. CD4+ T cells encounter
31,0% and 31,4% of the lymphocyte population in the peripheral lymph nodes of WT and
gzmA-/- mice respectively, but only 17,9% and 15,4% in the spleen (Fig 1A). In contrast, the
percentage of CD4+CD25+ T cells within the lymphocyte populations in peripheral lymph
nodes and spleen are comparable without differences betweenWT and gzmA-/- mice (7,3% ver-
sus 8,1% and 7,4% versus 8,4%) (Fig 1B). FACS analyses of Tregs from spleen and peripheral
lymph nodes did not reveal any significant differences. A comparable proportion of CD25+
Tregs in spleen (20,6% and 23,9%) and lymph nodes (18,3% and 19,0%) of WT and gzmA-/-
mice express the Th1-associated chemokine receptor CXCR3 enabling Tregs to migrate to in-
flammatory sites like GvHD target organs. More interestingly, although not significant, we de-
tected a higher proportion of CD62L+ expressing CD25+ T cells in the spleen of gzmA-/- mice
compared to WT mice (Fig 2A).
GZMA expressing Tregs protect against GvHD-related tissue damage of
the intestine
Interestingly, results from the in vitro proliferation-/inhibition assay show that GZMA is not
required for the direct inhibition of effector T cell proliferation (Fig 3). However, the more
complex role of GZMA in Treg cell mediated suppression in vivo was analyzed in a standard
model of acute GvHD. For this purpose, T cell depleted bone marrow cells (TCD BM) and
isolated T cell populations of wild type (WT) and gzmA-/- C57/BL6 donor mice were
Fig 1. GzmA-/- Tregs home efficiently to secondary lymphoid organs.CD4+ (A) and CD4+CD25+ Tregs (B) were isolated from spleen and peripheral
lymph node from wildtype (WT; n = 3) and gzmA-/-mice (n = 3) and analyzed by FACS. Expression values were calculated as a percentage of the T
lymphocyte population and mean values are presented as bar graphs. Students t-test did not reveal any significant differences betweenWT and gzmA-/-
Tregs.
doi:10.1371/journal.pone.0124927.g001
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transferred into the BALB/c recipient mice after lethal irradiation. Immune tolerant (TCD
BM + Teff + WT Tregs or gzmA-/- Tregs) and GvHDmice (TCD BM + Teff) were monitored
comparatively after adoptive T cell transfer for incidence, severity and clinical manifestation of
GvHD by clinical and histopathological grading (see Materials and Methods). After irradiation
and transplantation the body weight of recipient mice declined in all treatment groups and in-
creased again one week after transplantation (Fig 4A). However, two weeks after transplanta-
tion, mice from the GvHD group continuously lost weight in contrast to the immune tolerant
groups. Histopathological investigations confirm a severe inflammation especially in the small
and large intestine as GvHD target organs (Fig 4B). Recipients from the immune tolerant
group receiving WT Tregs recovered quickly and showed the highest body weight, whereas
mice after adoptive transfer of gzmA-/- Tregs recovered slower and reached a body weight simi-
lar to the immune tolerant mice receiving WT Tregs after 3 weeks with only limited/moderate
inflammation of GvHD target organs (Fig 4A). Moreover, clinical GvHD grading of mice re-
ceiving WT Tregs did not show any signs of inflammation or organ destruction in the liver and
intestinal tract three weeks after transplantation resulting in a pathology scoring of “0” for each
respective target organ (Fig 4C). In contrast, mice of the GvHD group developed a severe cellu-
lar inflammation as expected going along with organ destruction in form of crypt apoptosis in
Fig 2. GzmA-/- Tregs show no phenotypic alteration with respect to activation andmigration.WT Tregs (white bars) and gzmA-/- Tregs (grey bars)
were isolated from spleen (A) and peripheral lymph nodes (B) and analyzed by FACS. Expression values were calculated as a percentage of the CD4+ T
lymphocyte population and mean values are presented as bar graphs. Students t-test did not reveal any significant differences betweenWT and gzmA-/-
Tregs. Results are shown for n = 3WT and gzmA-/-mice each.
doi:10.1371/journal.pone.0124927.g002
Fig 3. GzmA-/- Tregs are highly suppressive in vitro. Regulatory T cells isolated fromWT (A) or gzmA-/-
(B) mice were co-cultured with CD4+CD25- T responder cells and activated with αCD3/αCD28. The
proliferation of the responder cells was measured by the dilution of the proliferation dye CFSE. (A) and (B)
show the proliferative response with or without (grey) regulatory T cells in a ratio 1:1. Percentage of
suppression is shown for WT and gzmA-/- Tregs in different effector T cell to regulatory T cell ratios (C).
doi:10.1371/journal.pone.0124927.g003
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the intestinal tract (cumulative mean pathology score of the small and large intestine: “4.8” and
“6.2”) and bile duct injury (mean pathology score of “2”). Notably, the adoptive transfer of
gzmA-/- Treg could not prevent GvHD efficiently. However, in the liver the degree of inflam-
mation and bile duct destruction was only mild (mean pathology score “1”) and in the GvHD
group significant severe GvHD-related signs could be observed (p<0.001). In contrast, gzmA-/-
Tregs could not efficiently protect from GvHD-related inflammation and organ destruction in
the intestinal tract with relevant crypt apoptosis detected in the small (mean pathology score
“2” and large intestine (mean pathology score “3”) (Fig 4C).
Discussion
Recently, we have reported that Tregs of GvHD patients may not effectively control alloreactive
immune responses due to defects with respect to suppressive/cytolytic capacities, migration
properties and clonal expansion [8]. Tregs of GvHD patients show a significant lower expres-
sion of GZMA early after SCT in comparison to immune tolerant patients never developing a
GvHD, but stable expression levels of granzyme B (GZMB). Whereas others could demonstrate
that GZMB is not required for Treg cell mediated suppression of murine GvHD [9] and there-
by supporting our results in patients after allogeneic SCT, confirmative functional analyses of
Fig 4. GzmA-/- Tregs are required for prevention of gastrointestinal GvHD. Lethally irradiated BALB/c mice (n = 9) received T cell depleted (TCD) bone
marrow cells (BM) together with CD4+CD25- T effector cells (squares, n = 3) and CD4+CD25+WT Treg cells (circle, n = 3) or CD4+CD25+ gzmA-/- Treg cells
(triangle, n = 3) fromWTmice. (A) Body weight of the recipients was monitored daily. (B) Histopathological investigations of liver, small and large intestine of
mice sacrified after 3 weeks. (C) Histopathological GvHD scoring 3 weeks after transplantation were graded for severity of inflammation and degree of organ
destruction resulting in an organ-specific cumulative pathology score. For statistical analysis student`s t-test was performed and p values <0.05 (*) were
considered significant, while p<0.01 (**) and p<0.001 (**) were considered highly significant.
doi:10.1371/journal.pone.0124927.g004
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GZMA are still missing. The ability of donor-type WT Treg cells to protect from acute GvHD
is well known [2–4,19]. In this report we now demonstrate that GZMA is a highly relevant ef-
fector molecule of Tregs for the prevention of GvHD, especially of the intestinal tract as target
organ. Our phenotypic analysis of gzmA-/- Tregs revealed an increased but not significant ex-
pression of the lymphoid homing receptor CD62L (L-selectin) on gzmA-/- Tregs compared to
WT Tregs in the spleen probably indicating a more efficient homing of gzmA-/- Tregs to sec-
ondary lymphoid tissues. Expression of CD62L+CD4+CD25+ Tregs has been described to be
pivotal for efficient migration of Tregs to priming sites of allogeneic immune responses. Only
CD62L+CD4+CD25+ Tregs prevent severe tissue damage to the colon and protected from lethal
GvHD [20] by inhibition of the expansion of donor derived activated CD4+CD25- T cells.
However, we could not detect a more efficient homing of gzmA-/- Tregs to secondary lymphoid
homing and their migration capacity and suppressive function is comparable to WT Tregs.
Therefore, additional factors in vivomight be responsible for the protection from inflammation
and crypt destruction in the small and especially large intestine by GZMA and not by GZMB
[9] expressing Tregs. Interestingly, upon activation CD4+CD25+ natural Tregs predominantly
express GZMA, while GZMB seems not to be inducible [13]. GZMA expressing Tregs may be
required to suppress/kill activated autologous immune cells that express endogenous inhibitors
of GZMB, such as serin proteinase inhibitor PI-9 [21]. Furthermore, Grossman et al. could
show that GZMA expressing Tregs exhibit a more effective cytotoxicity and were able to kill
autologous immune cells at a very low E:T ratio in comparison to GZMB expressing Tregs
[12]. The induction of apoptosis is not restricted to effector T cells but also involves APCs. In
this respect, human Tregs were found to induce apoptosis in B cells, monocytes, and DCs,
thereby mediating indirect regulation of T-cell responses [12]. Furthermore, GZMA can cleave
a number of extra cellular matrix proteins, and thus may facilitate migration of Tregs through
extracellular tissues. In contrast, GZMB has been shown to be required not only for cytolytic
regulation of lung inflammation by Tregs during acute viral lung infection [22] as well as for
Treg cell-contact dependent mediated inhibition of effector T cell function in tumor immunity
[23] and transplantation [24], but not for protection from GvHD [9]. Similar to WT Tregs the
adoptive transfer of gzmB-/- Tregs protected from lethal GvHD and organ damage. Differences
regarding the impact of GZMA and GZMB in GvHD prevention, especially for Treg cell medi-
ated protection from intestinal GvHD, might therefore be multifaceted and dependent on envi-
ronmental factors of the gastrointestinal tract. As also our human data support the high impact
of GZMA in Treg cell mediated protection from GvHD following allogeneic stem cell trans-
plantation further dissection of the molecular mechanism is warranted.
Supporting Information
S1 Fig. Gating strategies for analyses of CD4+ and CD4+CD25+ T cell populations. CD4+
and CD4+CD25+ Tregs were isolated from spleen and peripheral lymph node from wildtype
(WT) and gzmA-/- mice by MACS separation and stained with respective anti-mouse antibod-
ies for measurement by FACS Canto. Representative data of one WT and one gzmA-/- mice
are shown.
(TIF)
S2 Fig. Gating strategies for analyses of indicated T cell populations. Total CD4+25+ Treg
cells isolated from peripheral lymph nodes and spleens of WT and gzmA-/- mice were stained
with respective anti-mouse antibodies for measurement by FACS Canto. Representative data
of one WT and one gzmA-/-mice are shown.
(TIF)
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